雲頂新耀(01952.HK)「耐賦康」在澳門鏡湖醫院開出首張處方
雲頂新耀(01952.HK)公布,旗下全球首款對因治療IgA腎病藥物「耐賦康」,於昨日(18日)在澳門鏡湖醫院開出首張處方,是該產品在雲頂新耀亞洲授權區域內獲批後開出的首張處方。
公司並與澳門鏡湖醫院簽署戰略合作備忘錄,雙方將在腎臟疾病、自身免疫性疾病和感染性疾病等領域建立戰略合作,就相關治療領域的前沿進展、平台建設等加強合作。
另外,由中國初級衛生保健基金會發起的「保腎賦康援助項目(二期)」正式落地,公司預期可惠及更多急需用藥的中國患者。該項目將為中國大陸地區公民在中國澳門使用耐賦康的患者提供資金援助,以減輕患者家庭與社會負擔,提高患者生活質量。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.